{
    "name": "cidofovir",
    "comment": "Rx",
    "other_names": [
        "Vistide (DSC)"
    ],
    "classes": [
        "Antivirals",
        "CMV"
    ],
    "source": "https://reference.medscape.com/drug/cidofovir-342606",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: It is not known whether cidofovir is excreted in milk. It should not be administered to nursing mothers. The CDC advises HIV-infected women not to breast-feed to avoid postnatal transmission of HIV."
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: It is not known whether cidofovir is excreted in milk. It should not be administered to nursing mothers. The CDC advises HIV-infected women not to breast-feed to avoid postnatal transmission of HIV."
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Renal impairment is the major toxicity, and acute renal failure resulting in dialysis or contributing to death have occurred with as few as 1 or 2 doses",
                "Reduce nephrotoxicity risk by IV prehydration with normal saline, and administration of probenecid must be used with each infusion",
                "Renal function (serum creatinine and urine protein) must be monitored within 48 hr prior to each dose, and, if necessary, modify dose in renal function as appropriate",
                "Contraindicated if taking other nephrotoxic agents",
                "Neutropenia observed; monitor neutrophil counts",
                "Indicated only for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS)",
                "Animal studies showed cidofovir was carcinogenic, teratogenic, and caused hypospermia"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to cidofovir or probenecid",
                "SCr >1.5 mg/dL, CrCl <55 mL/min, urine protein >100 mg/dL (2+ proteinuria)",
                "Direct intraocular injection",
                "Concomitant nephrotoxic drugs"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of nephrotoxicity (dose-limiting)",
                "Risk of neutropenia",
                "Probenecid must be administered w/each dose: 2 g PO 3 hr before cidofovir, 1 g at 2 hr & 8 hr after completion of cidofovir infusion",
                "1 L saline IV with each cidofovir infusion; 1 add'l liter if pt can tolerate"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin and cidofovir both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "amphotericin B deoxycholate and cidofovir both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "contrast media (iodinated)",
            "description": {
                "common": "cidofovir and contrast media (iodinated) both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cidofovir and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ioversol",
            "description": {
                "common": "cidofovir and ioversol both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "cidofovir and neomycin PO both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "cidofovir and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "teicoplanin",
            "description": {
                "common": "cidofovir and teicoplanin both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "acyclovir",
            "description": {
                "common": "acyclovir and cidofovir both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bacitracin",
            "description": {
                "common": "cidofovir and bacitracin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Avoid concurrent use of bacitracin with other nephrotoxic drugs"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capreomycin",
            "description": {
                "common": "capreomycin and cidofovir both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carboplatin",
            "description": {
                "common": "carboplatin and cidofovir both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Concomitant use of cidofovir and agents with nephrotoxic potential is contraindicated. Such agents must be discontinued at least 7 days prior to starting therapy with cidofovir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cephaloridine",
            "description": {
                "common": "cephaloridine and cidofovir both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisplatin",
            "description": {
                "common": "cidofovir and cisplatin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Concomitant use of cidofovir and agents with nephrotoxic potential is contraindicated. Such agents must be discontinued at least 7 days prior to starting therapy with cidofovir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "colistin",
            "description": {
                "common": "cidofovir and colistin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, cidofovir.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gentamicin",
            "description": {
                "common": "cidofovir and gentamicin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "cidofovir and oxaliplatin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Concomitant use of cidofovir and agents with nephrotoxic potential is contraindicated. Such agents must be discontinued at least 7 days prior to starting therapy with cidofovir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pacritinib",
            "description": {
                "common": "pacritinib will increase the level or effect of cidofovir by  Other (see comment). Avoid or Use Alternate Drug. Concomitant administration of pacritinib (OCT1 inhibitor) with OCT1 substrates may increase the plasma concentrations of these substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "polymyxin B",
            "description": {
                "common": "cidofovir and polymyxin B both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, cidofovir.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "streptozocin",
            "description": {
                "common": "cidofovir and streptozocin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Concomitant use of cidofovir and agents with nephrotoxic potential is contraindicated. Such agents must be discontinued at least 7 days prior to starting therapy with cidofovir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tobramycin",
            "description": {
                "common": "cidofovir and tobramycin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zidovudine",
            "description": {
                "common": "cidofovir, zidovudine.\nEither increases levels of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: When cidofovir is administered concurrently with probenecid, zidovudine clearance may be decreased. Reduce dose of zidovudine by 50% on days of cidofovir/probenecid administration. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, cidofovir.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adefovir",
            "description": {
                "common": "adefovir and cidofovir both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabozantinib",
            "description": {
                "common": "cidofovir will increase the level or effect of cabozantinib by  Other (see comment). Use Caution/Monitor. MRP2 inhibitors increase cabozantinib toxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and cidofovir both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "cidofovir, elvitegravir/cobicistat/emtricitabine/tenofovir DF.\nEither increases toxicity of the other by decreasing renal clearance. Use Caution/Monitor. Toxicity may result from coadministration of emtricitabine and tenofovir with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "emtricitabine",
            "description": {
                "common": "cidofovir increases levels of emtricitabine by Other (see comment). Use Caution/Monitor. \nComment: Coadministration of emtricitabine with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of emtricitabine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "foscarnet",
            "description": {
                "common": "cidofovir and foscarnet both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "cidofovir, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, cidofovir.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Ifosfamide may enhance renal toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine, cidofovir.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Lomustine may enhance the toxicities of myelosuppressive agents. Monitor for increased risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methotrexate",
            "description": {
                "common": "cidofovir and methotrexate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor. May increase myelosupression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methoxyflurane",
            "description": {
                "common": "cidofovir and methoxyflurane both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paromomycin",
            "description": {
                "common": "cidofovir and paromomycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "cidofovir and pentamidine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peramivir",
            "description": {
                "common": "cidofovir increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptomycin",
            "description": {
                "common": "cidofovir and streptomycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "cidofovir and tenofovir DF both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and cidofovir both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of cidofovir by immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vancomycin",
            "description": {
                "common": "cidofovir and vancomycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, cidofovir.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "cidofovir, zidovudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of myelosuppression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "entecavir",
            "description": {
                "common": "cidofovir, entecavir.\nEither increases levels of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Infection",
            "percent": null
        },
        {
            "name": "Chills",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Amnesia",
            "percent": null
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Weakness",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Acne",
            "percent": null
        },
        {
            "name": "Skin discoloration",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Gastritis",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Amblyopia",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Ocular hypotony",
            "percent": null
        },
        {
            "name": "Tubular damage",
            "percent": null
        },
        {
            "name": "Proteinuria",
            "percent": null
        },
        {
            "name": "Elevated creatinine",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Diaphoresis",
            "percent": null
        },
        {
            "name": "Pallor",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Hallucinations",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Somnolence",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Hyperglycemia",
            "percent": null
        },
        {
            "name": "Hyperlipidemia",
            "percent": null
        },
        {
            "name": "Hypocalcemia",
            "percent": null
        },
        {
            "name": "Hypokalemia",
            "percent": null
        },
        {
            "name": "Dehydration",
            "percent": null
        },
        {
            "name": "Abnormal taste",
            "percent": null
        },
        {
            "name": "Stomatitis",
            "percent": null
        },
        {
            "name": "Glycosuria",
            "percent": null
        },
        {
            "name": "Hematuria",
            "percent": null
        },
        {
            "name": "Urinary incontinence",
            "percent": null
        },
        {
            "name": "Urinary tract infections",
            "percent": null
        },
        {
            "name": "Skeletal pain",
            "percent": null
        },
        {
            "name": "Retinal detachment",
            "percent": null
        },
        {
            "name": "Iritis",
            "percent": null
        },
        {
            "name": "Uveitis",
            "percent": null
        },
        {
            "name": "Abnormal vision",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Rhinitis",
            "percent": null
        },
        {
            "name": "Sinusitis",
            "percent": null
        },
        {
            "name": "Allergic reactions",
            "percent": null
        }
    ]
}